As pharmaceutical companies embrace antibody-drug conjugates (ADCs) as a way to treat cancer, drug services providers are ...

The "Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering. Antibody drug conjugates ...

A team of researchers have applied a novel blood test that can detect early signs of potentially fatal lung damage in cancer ...

Celltrion Inc. posted preclinical study results of two new antibody-drug conjugate (ADC) candidates – CT-P70 and CT-P71 – at ...

Antibody Drug Conjugates (ADCs) are a class of small molecule drugs (also known as a payload) and an antibody conjugated together by a chemical linker. ADCs are designed to target specific cells ...

ADC Therapeutics has stopped development of lead solid tumor candidate ADCT-601. The biotech axed the AXL-directed ...

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug ...

Chime Biologics, a leading global CDMO that enables its partners' success in biologics, and Waterstone, a reliable partner ...

The rise of antibody therapeutics is transforming drug discovery, providing highly specific treatments for complex diseases ...

non-small cell lung cancer and triple-negative breast cancer. The company also plans to initiate studies evaluating the therapy in combination with BioNTech’s antibody-drug conjugates.

Stephens has initiated coverage on Pyxis Oncology Inc (NASDAQ:PYXS), highlighting the company’s technology platform aimed at ...